which represent variably spliced isoforms (13) with unique FGFbinding specificities (14) .
FGF-R1 RNA is detected in the fetal rat from Day 18 of gestation and its expression remains relatively constant until 28 d after birth (15) , covering the period of postnatal alveologenesis. FGF-R1 binds FGF-1, FGF-2, FGF-3, FGF-4, and FGF-8, but not FGF-7 (16) . FGF-1 binds with equivalent affinity to FGF-R1␣(IIIc) and FGF-R1␣(IIIb), but FGF-2 binds with higher affinity to FGF-R1␣(IIIc) (17) . Also, a naturally occurring secreted form of FGF-R1 has a greater affinity for FGF-2 than for FGF-1 (18) .
Alveoli initially form from prealveolar saccules by a process of secondary septation, which involves the in-growth of secondary crests from the walls of the saccule, thus subdividing it into smaller gas exchange units, the alveoli (19) . Approximately 85% of alveoli form after birth in the human, whereas alveologenesis is a completely postnatal event in the rat (20) . In the neonatal rat, the most rapid increase in alveolar density occurs between Days 3 and 8 of life (21) , and alveolar formation is essentially complete by Day 21 of life (22) . In addition to cell proliferation, apoptosis of alveolar epithelial cells and interstitial fibroblasts is an important component of the lung remodeling that occurs during alveologenesis in both the rat and human (23) (24) (25) .
The growth factors, and growth factor receptors, that regulate the process of alveologenesis have not been defined. With respect to the FGF family, there is evidence to suggest that FGF-R3 and FGF-R4 interact to play a critical role in the postnatal formation of alveoli (11) , whereas epithelial cell FGF-R2 apparently does not play a role (26) . FGF-R1 is essential for murine embryonic development, with embryos carrying homozygous deletions of FGF-R1 dying in early gestation (27) . The contribution, if any, of the FGF-R1 to normal postnatal formation of alveoli has not, to our knowledge, been reported. On the basis of our previous observation that inhibition of ligand binding to the FGF-R1, using a truncated soluble FGF-R1␣(IIIc)/Fc chimeric protein (sFGF-R1), blocked restoration of alveologenesis in rats recovering from lung growth arrest induced with 95% oxygen (28) , we hypothesized that the FGF-R1␣(IIIc) would also play a critical role in physiologic postnatal alveologenesis.
Some of the results of these studies have been previously reported in the form of an abstract (29) .
METHODS

In Vivo Interventions
Animal studies were conducted according to criteria established by the Canadian Council on Animal Care and were approved by the Hospital for Sick Children Research Institute Animal Care Review Committee. Nine pups from each of three equal-sized litters received either phosphate-buffered saline (PBS), sFGF-R1, or a truncated soluble p75 neurotrophin receptor chimeric protein (sNGF-R; R&D Systems, Minneapolis, MN) in 100 l PBS (10 g/g body weight). Time points were selected to capture the rapid increase in alveolar density that occurs between Days 3 and 8 of life in the rat (21) . Intraperitoneal injections were given once, on Day 3 of life, via a 30-gauge needle into the right iliac fossa. For neutralizing antibody studies, 24 pups from four equal-sized litters were injected with either rabbit anti-human FGF-1/acidic FGF neutralizing antibody (R&D Systems), neutralizing mouse anti-human FGF-2/basic FGF (clone bFM-1; Upstate, Lake Placid, NY), or isotype IgG on Days 3, 4, 5, and 6 of life (10 g/g body weight). Animals were killed on Day 7 of life.
Lung DNA Content and Synthesis
DNA content and synthesis ([ 3 H]thymidine incorporation into DNA) were measured as previously described (28, 30) . Intraperitoneal [ 3 H]thymidine (1 Ci/g) was injected 2 h before removal of lung tissue. Lungs were weighed and then homogenized for DNA isolation (31) .
TUNEL Assay
Details of the terminal deoxynucleotide nick end labeling (TUNEL) assay are provided in the online supplement.
Western Blot Analyses
Western blots of lysates from perfused lung tissue were performed as previously described (32) . Protein content was measured as described by Bradford (33) . Details of antibody sources, dilutions, and immunoprecipitation are provided in the online supplement. Blots were imaged and bands quantified by enhanced chemiluminescence detection as previously described (32) . The software used calculated integrated band densities after subtraction of background values (FluorChem 8000, Ver. 3.04A; Alpha Innotech Corp., San Leandro, CA) (32) .
Immunohistochemistry
Lungs were perfusion-fixed at a constant inflation pressure of 20 cm water. Details are provided in the online supplement. Intraperitoneal injection (20 g/g) of bromodeoxyuridine (BrdU) was performed 2 h before animals were killed. Immunohistochemical staining of paraformaldehydefixed paraffin-embedded lung tissue was with a BrdU In-Situ Detection Kit (BD Biosciences Pharmingen, San Diego, CA). Frozen sections were used to stain for cleaved caspase 3. Details are provided in the online supplement.
Morphometric Analyses
Morphometric assessments were performed on coded images to mask the treatment category. Images were captured with OpenLab, version 3.5.2 (Improvision, Guelph, ON, Canada), using a Leica camera and microscope (Leica Microsystems GmbH, Wetzlar, Germany) attached to a Macintosh computer (Mac 10.3.5 operating system; Apple Computer, Cupertino, CA). Because of regional variations in lung maturation (34) , all assessments were performed on the right middle lobe. Mean linear intercept, tissue fraction, secondary crest density, and alveolar density were calculated as previously described (35) .
Data Presentation
All values are presented as mean Ϯ SEM. Parametric data were subjected to one-way analysis of variance (ANOVA), followed by StudentNewman-Keuls post hoc test for between-group differences (36) . For categorical data, a Kruskal-Wallis ANOVA was used to detect differences across groups, followed by the Mann-Whitney test for betweengroup differences. A p value Ͻ 0.05 was regarded as statistically significant.
RESULTS
Reduced FGF-R1 Phosphorylation after Injections of sFGF-R1 or Neutralizing Antibody to FGF-2 FGF-R1 was immunoprecipitated with an antibody against the C-terminal domain of the FGF-R1 and was analyzed by immunoblotting with either anti-FGF-R1 (N-terminal domain) or an antiphosphotyrosine antibody. Injection of sFGF-R1 or FGF-2 neutralizing antibody, but not FGF-1 neutralizing antibody, reduced phosphorylation of the endogenous FGF-R1 (Figure 1 ).
Increased Lung Tissue Fraction in sFGF-R1-treated Pups
Day 7 pups that had been injected with the control sNGF-R had lungs with a similar histologic appearance to those that had been injected with the vehicle alone. However, pups that had been injected with the truncated sFGF-R1 had lungs with an obvious increase in interstitial thickness between Days 3 and 7, when compared with those that had been injected with the vehicle alone ( Figure 2 ). Morphometric analysis of lung tissue, after intervention studies with the sFGF-R1, confirmed a significant increase in tissue fraction (Table 1) .
Paradoxical Changes in Lung DNA Content and Synthesis in sFGF-R1-treated Pups
Likely explanations for an intervention causing an increase in cellularity are stimulation of lung cell proliferation or inhibition of cell death. Our initial step, therefore, was to measure lung weight, lung DNA content, and lung DNA synthesis, as assessed by [ 3 H]thymidine incorporation into DNA. For these particular measurements, we did not include the use of the control sNGF-R, because we have previously demonstrated its lack of effect on these parameters (28, 37) . Injection of the truncated sFGF-R1 had no significant effect on body weight, lung weight, or total lung protein content. Total lung DNA content was significantly increased in sFGF-R1-treated animals, but was accompanied by a marked inhibition of DNA synthesis, as assessed by [ 3 H]thymidine incorporation into DNA (Table 2) . To confirm the inhibitory effect on DNA synthesis, in the absence of an effect on total DNA content, we used BrdU incorporation into lung tissue as an additional marker for cell proliferation (38) . Lungs from 7-d-old rats injected with PBS or sNGF-R had large numbers of BrdU-positive cells, but there was an obvious reduction in the number of BrdU-positive cells in lung tissue from the Day 7 rat pups that had received the sFGF-R1 (Figure 3 ). This was confirmed by counting the number of BrdU-positive cells per unit area (Figure 4 ). That this inhibition of lung cell DNA synthesis translated into an impairment of alveolar formation was confirmed by morphometric analysis. Injection of the sFGF-R1 resulted in Definition of abbreviations: NR-IgG ϭ normal rabbit IgG; NM-IgG ϭ normal mouse IgG; sFGF-R1 ϭ soluble fibroblast growth factor receptor 1; sNGF-R ϭ soluble p75 neurotrophin receptor chimeric protein.
Kruskal-Wallis analysis of variance was used to detect differences across the groups, followed by the Mann-Whitney test for differences between two groups. * p Ͻ 0.05 compared with values for animals that had received vehicle alone. a significant increase in mean linear intercept and a significant decrease in the number of secondary crests ( Table 1) .
Inhibition of Apoptosis by sFGF-R1
The reduction in both [ 3 H]thymidine incorporation into DNA and BrdU-positive cells, after treatment with sFGF-R1, in the presence of an increased tissue fraction, suggested that the intervention had inhibited the apoptosis-mediated thinning of the interstitium, which is normally seen after birth. Attempts to assess apoptosis in the lung interstitium using the TUNEL assay were unsuccessful, due to labeling of neonatal erythrocytes (Figure E1 of Figure 5A ). The number of cleaved caspase-3-positive cells appeared to be reduced in pups that had received sFGF-R1 ( Figure 5B ), which was confirmed by quantifying the number of caspase-3-positive cells per unit area ( Figure 5C ). We then went on to examine a panel of anti-and proapoptotic proteins by Western blot, as shown in Figure 6A . Pups that had received sFGF-R1 had an unchanged expression of Fas, but did have a reduction in the expression of the proapoptotic protein Bax, and an increase in the antiapoptotic protein Bcl-x L . The expression of mitochondria-derived cytoplasmic cytochrome c was inhibited by the injection of sFGF-R1. The contents of cleaved caspases 3 and 7 were also suppressed by the injection of sFGF-R1. Densitometric analysis was used to confirm the statistical significance of these changes ( Figure 6B ).
Differing Effects of Anti-FGF-1 and Anti-FGF-2
FGF receptors are generally promiscuous, binding multiple FGF family members. Both FGF-1 and FGF-2 bind with high affinity to the FGF-R1. We used intraperitoneal injections of neutralizing antibodies to explore their possible contribution to the effects mediated by the FGF-R1. Anti-FGF-2, but not anti-FGF-1, significantly inhibited phosphorylation of the FGF-R1 (Figure 1 ) and a downstream mediator, Erk1/2 ( Figure E2 ). Interestingly, neither the anti-FGF-1 nor the anti-FGF-2 antibodies had any apparent effect on DNA synthesis, as assessed by BrdU immunoreactivity ( Figure E3 ), which was confirmed by counting labeled cells ( Figure E4 ), suggesting that inhibition of binding of another FGF family member accounted for the inhibition of DNA synthesis observed with the sFGF-R1. There was no obvious effect of the neutralizing antibody to FGF-1 on either the tissue fraction (Table 1) or the apparent thickness of the lung interstitium ( Figure 7 ). In contrast, neutralizing antibodies to FGF-2 did increase the tissue fraction (Table 1) and caused an obvious thickening of the lung interstitium (Figure 7 ), comparable to that observed after injection of the sFGF-R1. Neither of the antibodies to FGF-1 or FGF-2 had any significant effect on mean linear intercept, but, as observed with the sFGF-R1, both significantly decreased the number of secondary crests. All three interventions reduced the alveolar density, but this effect was only statistically significant for the FGF-2 antibody (Table 1) . By Western blot, neither the FGF-1 nor the FGF-2 antibodies had any effect on Fas expression ( Figure 8A) , Bax, or cleaved caspase-3 expression (data not shown). However, both antibodies caused an increase in the antiapoptotic protein Bcl-x L , and a decrease of cytoplasmic cytochrome c and cleaved caspase 7 ( Figure 8A ), which were statistically significant ( Figure 8B ).
BODY AND LUNG WEIGHTS, LUNG PROTEIN AND DNA CONTENTS, AND DNA SYNTHESIS IN DAY 7 PUPS THAT HAD RECEIVED INJECTIONS OF SOLUBLE RECEPTOR OR VEHICLE
DISCUSSION
The primary intervention used in this study was the injection of a recombinant human sFGF-R1␣(IIIc)/Fc chimera. This protein is initially derived from a DNA sequence that encodes the entire extracellular domain of the human FGF-R1␣(IIIc), fused to the carboxy-terminal Fc region of human IgG1 via a polypeptide linker. There is a very high degree of homology between the amino acid sequences for the FGF-R1 proteins from different species (14) , making it likely that the recombinant human sFGF-R1␣(IIIc)/Fc chimera used in our studies has a similar affinity for members of the FGF family as does the endogenous receptor, which includes binding of both FGF-1 and FGF-2 (18) . The desired effect of injecting the sFGF-R1 was for it to act as a decoy to prevent binding of those ligands that would normally have bound to the endogenous FGF-R1␣(IIIc). To confirm that there were no nonspecific effects of the fused Fc portion of the chimera, we used an sNGF-R/Fc chimera as a control, which we have previously found to have no effect on postnatal lung growth (28, 37) . On the basis of our previous observations, with a model of lung growth arrest followed by recovery (28), we were not surprised that the truncated sFGF-R1 caused inhibition of DNA synthesis, as assessed by both [ 3 H]thymidine and BrdU incorporation, and impairment of alveolarization, as assessed by morphometry. What we had not anticipated, however, was that this would occur in the absence of any change in lung weight or protein content. It became apparent from lung morphology and morphometry that this was due to an increase in the tissue fraction, secondary to an increased cellularity of the lung interstitium, as reflected by an increase in lung DNA content. That this increase in DNA content was not accompanied by an increase in lung weight or protein content is consistent with the observed reduction in protein-to-DNA ratio. The most obvious explanation was that apoptosis, induced by the binding of one or more FGF family members to the endogenous FGF-R1, was inhibited by the binding of these ligands to the decoy truncated sFGF-R1␣(IIIc)/Fc chimera. Apoptosis is involved in the remodeling of both rat and human lung during both normal prenatal and postnatal development (24, 25) . Postnatally, the role of apoptosis appears to be in ridding the lung of excess fibroblasts and epithelial cells so as to increase the gas exchange surface area (23, 25) . Support for the inhibition of apoptosis by the sFGF-R1 came from the measurement of proapoptotic and antiapoptotic proteins. Treatment with the sFGF-R1 caused a reduction in the concentration of the proapoptotic protein Bax, an increased concentration of the antiapoptotic protein Bcl-x L , and an inhibition of the downstream factors cytoplasmic cytochrome c, cleaved caspase 3, and cleaved caspase 7, without affecting Fas. Fas had been implicated in the postnatal apoptosis of murine lung alveolar epithelial cells, and this pathway was inhibited in vitro by FGF-7 (39, 40) .
FGF-R1␣(IIIc) binds several members of the FGF family, including high-affinity binding to FGF-1 and FGF-2. We specifically addressed the possible impact of the decoy sFGF-R1 binding to these two ligands by the use of neutralizing antibodies to FGF-1 and FGF-2. The neutralizing antibody to FGF-2, but not the antibody to FGF-1, increased interstitial thickness and the tissue fraction, to a degree comparable to that observed with the decoy sFGF-R1. The observed effect on lung histology by the decoy sFGF-R1 could, therefore, be completely accounted for by its binding to FGF-2. There are precedents for FGF-2 serving such a function, in that it has been reported to promote apoptosis and suppress granulation tissue formation in acute incision wounds (41) , and induce cell death in Ewing's sarcoma (42) and various tumor cell lines (43) (44) (45) .
The two major routes to apoptosis are through the intrinsic and extrinsic pathways. Both pathways ultimately lead to the cleavage of inactive procaspase molecules into active caspase proteins (46) . Caspases are a family of aspartate-specific cysteine proteases that cleave and degrade a specific subset of cellular proteins in cells undergoing apoptosis (47) . Initiator caspases, including caspases 8 and 9, are responsible for either directly or indirectly activating various effector caspases, including caspases 3, 6, and 7. We used caspases 3 and 7 as markers for this final component of the apoptotic pathway, which was inhibited by the decoy sFGF-R1. Initiation of this terminal cascade may be through the extrinsic pathway, which is induced by binding of death-signal ligands, such as FasL, to integral membrane proteins, such as Fas, with subsequent caspase-8 activation (48). We found no evidence for an effect of the sFGF-R1 on Fas expression. Alternatively, apoptosis can be initiated through an intrinsic pathway, mediated by the mitochondria. The Bcl-2 family consists of several proapoptotic and antiapoptotic proteins that determine cell death and survival by controlling mitochondrial membrane ion permeability, cytochrome c release, and the subsequent activation of caspase 9 (49, 50) . Injection of the sFGF-R1 inhibited expression of the proapoptotic protein Bax and stimulated expression of the antiapoptotic protein Bcl-x L . There was a corresponding downstream inhibition of mitochondrial release of cytochrome c and a decrease in the expression of cleaved caspases 3 and 7. These findings suggest that the decoy sFGF-R1 acts through binding an FGF family member, or members, to prevent apoptosis initiated through the intrinsic pathway, and that the FGF-R1␣(IIIc) can act as a death receptor.
To determine if FGF-1 or FGF-2 were FGF family members mediating this process, we selectively inhibited their binding to FGF receptors by the use of neutralizing antibodies. The antibody to FGF-2, but not the antibody to FGF-1, replicated the interstitial thickening and increased tissue fraction observed with the sFGF-R1. This may have resulted from the anti-FGF-2 antibody inhibiting FGF-R1 and downstream Erk1/2 phosphorylation. Anti-FGF-1 had no effect on this transduction pathway.
Interestingly, of the apoptosis-related proteins studied, the neutralizing antibody to FGF-2 affected the antiapoptotic protein Bcl-x L , cytochrome c release, and cleaved caspase-7 expression, in a similar fashion to the decoy sFGF-R1. Bcl-x L was also increased to a lesser degree after treatment with the anti-FGF-1 antibody, but this treatment did not affect the tissue fraction. It seems reasonable to assume that the increase in Bcl-x L observed after treatment with the decoy sFGF-R1 can be attributed to its binding of FGF-1 and FGF-2. Because neither the anti-FGF-1 antibody nor the anti-FGF-2 antibody affected Bax expression, the increase in the expression of this protein after treatment with the sFGF-R1 must be accounted for by the binding of ligands other than FGF-1 or FGF-2. However, the contribution of these ligands, and the effect on Bax, may not be essential because the neutralizing antibody to FGF-2 alone was sufficient to increase the tissue fraction. FGF-R1 activation leads to receptor tyrosine phosphorylation and increased phosphorylation of three major intracellular pathways. These are the Ras-mitogenactivated protein (MAP) kinase (Erk1/2, p38, c-Jun N-terminal kinases [JNKs]) pathway, the phosphoinositide-3 kinase (PI-3) kinase-Akt pathway, and the phospholipase C (PLC␥) pathway (51) . Our data are consistent with the effect of inhibiting FGF-2 binding to the FGF-R1 being mediated, at least in part, through the MAP kinase (Erk1/2) pathway. Inhibition of FGF-1 binding to its receptors did not affect FGF-R1 tyrosine phosphorylation, suggesting that its effects in the neonatal lung, if any, are mediated through binding to alternative FGF receptors.
In summary, ligand binding to the FGF-R1␣(IIIc) is an effector of postnatal lung growth. In addition, both FGF-2 and the FGF-R1␣(IIIc) appear to regulate the physiologic lung cell apoptosis normally seen shortly after birth.
